Autres langues AlzeCure Pharma AB

Actions

ALZCUR

SE0010133785

Temps Différé Nasdaq Stockholm Autres places de cotation 11:57:18 15/05/2024			Varia. 5j.	Varia. 1 janv.
1,765 ^SEK	-0,84%		-1,12%	-43,25%

14/05	AlzeCure Pharma AB (publ) approuve l'élection de Jan Lundberg en tant que nouveau membre ordinaire du conseil d'administration	CI
25/04	AlzeCure Pharma AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg elected as a new board member	10:00
AlzeCure Pharma AB Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors	14/05
Communiqué from the annual general meeting of AlzeCure Pharma on 14 May 2024	14/05
AlzeCure reports anti-inflammatory effects with NeuroRestore ACD856 with relevance to Alzheimer's leading to new patent application	13/05
AlzeCure Pharma publishes prospectus	29/04
AlzeCure publishes its interim report for January – March 2024	25/04
AlzeCure Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg invests in AlzeCure and is proposed for election to its board	10/04
Jan Lundberg acquired an unknown minority stake in AlzeCure Pharma AB (OM : ALZCUR).	10/04
AlzeCure Pharma publishes its Annual Report for 2023	04/04
AlzeCure presents new data regarding the TrkA-NAM pain project at IASP 2024	03/04
AlzeCure Pharma AB Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024	03/04
AlzeCure to partake in Redeye Theme, Alzheimer on March 21	15/03
AlzeCure to partake in Redeye Theme: Alzheimer on March 21	14/03
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference	07/03
AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer's conference	07/03
AlzeCure Pharma AB Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's	05/03
AlzeCure publishes clinical results supporting continued development of NeuroRestore ACD856 against Alzheimer's	05/03
AlzeCure's Alzheimer's project NeuroRestore ACD856 is granted an additional patent	29/02
AlzeCure publishes its Year-end report for January – December 2023	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues AlzeCure Pharma AB

Actions

ALZCUR

SE0010133785

Autres langues

Filtres